Great consistent results but it's curious that we didn't get data for the patients in stage 2 for the nsclc or the head and neck portions. The nsclc stage 2 has been fully recruited for a while so some patients would of been reportable.
personally dont think it's a bad thing, if anything Merck might be wanting these results to stay to themselves and IMM as leverage is lost if the results are released and as good as we've got so far.
Ann: Improving results from stage 1 of TACTI-002 ph II trial, page-3
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.025(5.95%) |
Mkt cap ! $562.6M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 39.5¢ | $1.293M | 3.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 245115 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 41012 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |